Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
Clinical trial of tacrolimus versus cyclosporine in lung transplantation.
Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, Hardesty RL, Weyant RJ, Griffith BP. Keenan RJ, et al. Among authors: paradis il. Ann Thorac Surg. 1995 Sep;60(3):580-4; discussion 584-5. doi: 10.1016/0003-4975(95)00407-C. Ann Thorac Surg. 1995. PMID: 7545889 Clinical Trial.
CONCLUSIONS: This trial demonstrates the advantage of tacrolimus in reducing the risk of obliterative bronchiolitis, the most important cause of long-term morbidity and mortality after lung transplantation....
CONCLUSIONS: This trial demonstrates the advantage of tacrolimus in reducing the risk of obliterative bronchiolitis, the most important caus …
Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management.
Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, Yousem SA, Close JM, Zeevi A, Duquesnoy RJ, et al. Bando K, et al. Among authors: paradis il. J Thorac Cardiovasc Surg. 1995 Jul;110(1):4-13; discussion 13-4. doi: 10.1016/S0022-5223(05)80003-0. J Thorac Cardiovasc Surg. 1995. PMID: 7609567 Free article.
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipients), obliterative bronchiolitis is the most significant long-term complication after pulmonary transplantation. Because of its importance, we examined donor-recipient charac …
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipients), obliterative bronchiolitis is the m …
Comparison of outcomes after single and bilateral lung transplantation for obstructive lung disease.
Bando K, Paradis IL, Keenan RJ, Yousem SA, Komatsu K, Konishi H, Guilinger RA, Masciangelo TN, Pham SM, Armitage JM, et al. Bando K, et al. Among authors: paradis il. J Heart Lung Transplant. 1995 Jul-Aug;14(4):692-8. J Heart Lung Transplant. 1995. PMID: 7578177
BACKGROUND AND METHODS: To determine the long-term functional outcome for single versus bilateral lung transplant for nonseptic obstructive lung disease, we compared the results from 39 single and nine bilateral lung transplant procedures. ...
BACKGROUND AND METHODS: To determine the long-term functional outcome for single versus bilateral lung transplant for nonseptic obstr …
A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.
Duncan SR, Grgurich WF, Iacono AT, Burckart GJ, Yousem SA, Paradis IL, Williams PA, Johnson BA, Griffith BP. Duncan SR, et al. Among authors: paradis il. Am J Respir Crit Care Med. 1994 Jul;150(1):146-52. doi: 10.1164/ajrccm.150.1.8025741. Am J Respir Crit Care Med. 1994. PMID: 8025741 Clinical Trial.
Intravenous catheters for ganciclovir administration resulted in four complications among three of the subjects in Group G (23%). The short-term benefits of ganciclovir were ultimately limited, moreover, in that cumulative rates of CMV and prevalence of OB are now similar …
Intravenous catheters for ganciclovir administration resulted in four complications among three of the subjects in Group G (23%). The short- …
Lung transplantation at the University of Pittsburgh: 1982 to 1994.
Kawai A, Paradis IL, Keenan RJ, Hardesty RL, Hattler BG, Pham SM, Griffith BP. Kawai A, et al. Among authors: paradis il. Clin Transpl. 1994:111-20. Clin Transpl. 1994. PMID: 7547530
Although the tailored antibiotic treatment has significantly reduced the risk of bacterial pneumonia within 2 weeks after operation, infection is still a major cause of death for long-term recipients. Extensive studies need to be continued to understand the pathogenesis of …
Although the tailored antibiotic treatment has significantly reduced the risk of bacterial pneumonia within 2 weeks after operation, infecti …
Recurrence of sarcoidosis in pulmonary allograft recipients.
Johnson BA, Duncan SR, Ohori NP, Paradis IL, Yousem SA, Grgurich WF, Dauber JH, Griffith BP. Johnson BA, et al. Among authors: paradis il. Am Rev Respir Dis. 1993 Nov;148(5):1373-7. doi: 10.1164/ajrccm/148.5.1373. Am Rev Respir Dis. 1993. PMID: 8239178
Pulmonary transplantation appears to be an efficacious therapy for end-stage sarcoidosis, but the long-term sequelae of the increased acute rejection and recurrent sarcoidosis in the allograft remain to be determined....
Pulmonary transplantation appears to be an efficacious therapy for end-stage sarcoidosis, but the long-term sequelae of the increased …
Lung transplantation at the University of Pittsburgh.
Griffith BP, Bando K, Armitage JM, Hattler BG, Keenan RJ, Hardesty RL, Komatsu K, Konishi H, Paradis IL. Griffith BP, et al. Among authors: paradis il. Clin Transpl. 1992:149-59. Clin Transpl. 1992. PMID: 1306693
If the recipient survives the initial hospital stay, the likelihood of survival at 5 years is approximately 80%. The primary long-term complication is obliterative bronchiolitis which is poorly understood and difficult to treat. ...
If the recipient survives the initial hospital stay, the likelihood of survival at 5 years is approximately 80%. The primary long-term …